Starkage Therapeutics SAS has established a research collaboration with Gustave Roussy to characterize cellular senescence induced by standard-of-care treatments in a series of digestive cancers.
After reporting in April that its gastrointestinal reprogramming product (Garp) failed to meet the primary efficacy endpoint in a phase II trial in irritable bowel syndrome (IBS), Anatara Lifesciences Ltd. conducted a further analysis that shows a positive trend toward efficacy.
After reporting in April that its gastrointestinal reprogramming product (Garp) failed to meet the primary efficacy endpoint in a phase II trial in irritable bowel syndrome (IBS), Anatara Lifesciences Ltd. conducted a further analysis that shows a positive trend toward efficacy.
DP Technology Ltd. has nominated DPT-0218, a novel small molecule targeting Kv1.3, as a preclinical candidate for the treatment of various autoimmune diseases, including inflammatory bowel disease and atopic dermatitis.
Bariatek Medical SA’s team of inventors reported on a patent for a delivery system for introducing or deploying a gastrointestinal implant, particularly a bypass sleeve used to treat obesity and diabetes.
Limaca Medical Ltd. received U.S. FDA 510(k) clearance for its Precision for gastrointestinal (GI) endoscopic ultrasound (EUS) biopsy device which the company said allows for faster, more efficient and safer collection of tumor tissue samples. The approval follows the receipt of breakthrough device designation, and the deployment of the device into the U.S. market should lead to more efficient and effective diagnosis of GI cancers.
Neuraxis Inc. has initiated a clinical study to evaluate the efficacy of its IB-Stim neuromodulation system in treating children with post-concussion syndrome (PCS). The aim is to see whether IB-Stim can ease the constellation of symptoms that occur after mild traumatic brain injury such as headaches, dizziness and problems with concentration and memory.
Magentiq-Eye Ltd. received U.S. FDA 510(k) clearance for its Magentiq-Colo, an artificial intelligence (AI) gastrointestinal software system that helps detect lesions in real time during colonoscopy procedures. With the rate of colorectal cancer expected to increase steadily through the decade, the company hopes that Magentiq-Colo will offer the gastroenterology community and its patients a significant increase in the adenoma detection rate.
Atmo Biosciences Ltd. is gearing up for pivotal trials of its ingestible gas-sensing capsule after a clinical study supported the gas capsule’s ability to determine its location in the gastrointestinal tract.
In recent years enteric glial cells have moved on from being regarded as bit part players passively supporting intestinal epithelial cells, to being recognized as having a fundamental role in gastrointestinal physiology.
